Obesity Clinical Trial
Official title:
Healthy Lifestyle Promotion Program as a Strategy to Improve Obesity Parameters, Cardiovascular and Metabolic Risk Factors in Yaquis Indigenous in the State of Sonora
Verified date | January 2020 |
Source | Centro de Investigación en Alimentación y Desarrollo A.C. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Obesity has become an epidemic worldwide and is considered one of the main causes related to type 2 diabetes. The World Health Organization reported that in 2016, 39% of adults were overweight, while the percentage of obesity was 13%, together 1900 million people were overweight/obese. While in 2014 it was reported that 8.5% of the population in the world suffered from type 2 diabetes. On the other hand, in the national context, the last report of 2016 that 72.5% of the Mexican population suffers from overweight/obesity. In addition, in 2006, 14.4% of Mexicans suffered from type 2 diabetes. Obesity is a complex chronic state that is developed by an imbalance between the energy ingested and the energy expended. In addition, obesity is considered a chronic inflammatory state of low degree of cause of the immune response generated, as a consequence of the increase of adipose tissue; what explains the imbalance in the markers of inflammation. This inflammation condition has been related to the generation of insulin resistance, the increase in glucose levels and the appearance of various pathologies such as type 2 diabetes and other risk factors for cardiovascular diseases. The Yaqui ethnic group is located in the center-south zone of the state of Sonora, distributed in 8 traditional villages. A recent study conducted in the Yaqui community reported a prevalence of overweight and obesity of 25% and 43% respectively. In 2008, a prevalence of type 2 diabetes of 18.3% was reported in its inhabitants. On the other hand, there are successful programs in reducing body weight through interventions aimed at modifying lifestyles such as eating habits and physical function called Lifestyle Modification Programs. These programs have been supported through controlled and randomized clinical trials. Such is the case of the Diabetes Prevention Program. Which has achieved weight reduction and increased physical activity in the subjects treated. The Diabetes Prevention Program has been recognized and adapted for the Centers for Disease Control and Prevention and has been dubbed the "National Diabetes Prevention Program". The present study is a translational research clinical trial to evaluate the effectiveness of a program to promote the parameters of obesity and diabetes in the cardiovascular communities in the Yaqui community of the state of Sonora.
Status | Active, not recruiting |
Enrollment | 100 |
Est. completion date | March 2021 |
Est. primary completion date | February 20, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility | Inclusion Criteria: - Men and women being of the Yaqui tribe - Age 20 years and less than 65 - Overweight or obese (BMI =25 kg/m2) - FINDRISC score of 12 or higher - Sign up the consent form and wish to participate Exclusion Criteria: - Subjects with diagnosis previous of diabetes - Uncontrolled hypertension (systolic blood pressure =160 mmHg and diastolic blood pressure =100 mmHg) - Renal insufficiency - Hepatopathies - Neoplasms - Inflammatory and traumatic rheumatoid arthritis - Cardiovascular disease - Chronic obstructive pulmonary disease - Thyroid disease - Systemic lupus erythematosus - Inflammatory bowel disease - HIV - Psoriasis - Mesangial proliferative glomerulonephritis - Seriously ill - Bacterial and viral infections at the time of taking the blood sample - Pregnant women and/or stage of lactation - Subjects with limitations to carry out physical exercise - Subjects that have participated in another similar program - Subjects in pharmacological treatment for obesity - People under pharmacological treatment that alter glucose tolerance and lipid levels |
Country | Name | City | State |
---|---|---|---|
Mexico | Dispensario médico | Cd. Obregon | Loma De Guamúchil |
Mexico | Dispensario médico | Guaymas | Pótam |
Mexico | Dispensario médico | Guaymas | Tórim |
Mexico | Dispensario médico | Guaymas | Vícam |
Lead Sponsor | Collaborator |
---|---|
Centro de Investigación en Alimentación y Desarrollo A.C. |
Mexico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Body weight (kg) | Change in body weight | Change in body weight from baseline to 6 months and change in body weight from baseline to 12 months | |
Primary | Triglycerides (mg/dL) | Change in triglycerides | Change in triglycerides from baseline to 6 months and change in triglycerides baseline to 12 months | |
Primary | Fasting glucose (mg/dL) | Change in fasting glucose | Change in fasting glucose from baseline to 6 months and change in fasting glucose from baseline to 12 months | |
Primary | IL-6 (pg/ml) | Change in IL-6 | Change in IL-6 from baseline to 12 months | |
Secondary | Body Mass Index (kg/m2) | Change in Body Mass Index | Change in Body Mass Index from baseline to 6 months and change in Body Mass Index from baseline to 12 months | |
Secondary | Waist circumference (cm) | Change in waist circumference | Change in waist circumference from baseline to 6 months and change in waist circumference from baseline to 12 months | |
Secondary | Body fat percentage (%) | Change in body fat percentage | Change in body fat percentage from baseline to 6 months and change in body fat percentage from baseline to 12 months | |
Secondary | Fasting insulin (mg/dL) | Change in fasting insulin | Change in fasting insulin from baseline to 6 months and change in fasting insulin from baseline to 12 months | |
Secondary | Total cholesterol (mg/dL) | Change in total cholesterol | Change in total cholesterol from baseline to 6 months and change in total cholesterol from baseline to 12 months | |
Secondary | LDL-cholesterol (mg/dL) | Change in LDL-cholesterol | Change in LDL-cholesterol from baseline to 6 months and change in LDL-cholesterol from baseline to 12 months | |
Secondary | HDL-cholesterol (mg/dL) | Change in HDL-cholesterol | Change in HDL-cholesterol from baseline to 6 months and change in HDL-cholesterol from baseline to 12 months | |
Secondary | Systolic and diastolic blood pressure (mmHg) | Change in systolic and diastolic blood pressure | Change in systolic and diastolic blood pressure from baseline to 6 months and change in systolic and diastolic blood pressure from baseline to 12 months | |
Secondary | Physical activity (minutes/week) | Change in physical activity | Change in physical activity from baseline to 6 months and change in physical activity from baseline to 12 months | |
Secondary | Tumor Necrosis Factor-a (TNF-a) (pg/ml) | Change in TNF-a | Change in TNF-a from baseline to 12 months | |
Secondary | Adiponectin (µg/ml) | Change in adiponectin | Change in adiponectin from baseline to 12 months | |
Secondary | Body weight (kg) | Change in body weight | Change in body weight from 6 months to 12 and 18 months | |
Secondary | Body Mass Index (kg/m2) | Change in body mass index | Change in body mass index from 6 months to 12 and 18 months | |
Secondary | Waist circumference (cm) | Change in waist circumference | Change in waist circumference from 6 months to 12 and 18 months | |
Secondary | Body fat percentage (%) | Change in body fat percentage | Change in waist circumference from 6 months to 12 and 18 months | |
Secondary | Fasting glucose (mg/dL) | Change in fasting glucose | Change in fasting glucose from 6 months to 12 and 18 months | |
Secondary | Total cholesterol (mg/dL) | Change in total cholesterol | Change in total cholesterol from 6 months to 12 and 18 months | |
Secondary | LDL-cholesterol (mg/dL) | Change in LDL-cholesterol | Change in LDL-cholesterol from 6 months to 12 and 18 months | |
Secondary | HDL-cholesterol (mg/dL) | Change in HDL-cholesterol | Change in HDL-cholesterol from 6 months to 12 and 18 months | |
Secondary | Systolic and diastolic blood pressure (mmHg) | Change in systolic and diastolic blood pressure | Change in systolic and diastolic blood pressure from 6 months to 12 and 18 months | |
Secondary | Physical activity (minutes/week) | Change in physical activity | Change in physical activity from 6 months to 12 and 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |